Under the terms of the agreement, Ciphergen will analyze samples using its suite of proteomic solutions, pattern track process, and ProteinChip system. Financial terms were not disclosed.
Gail Page, president and CEO of Ciphergen, expressed her pleasure at the extension of the collaboration, saying that the companies share the vision “to accelerate and streamline development of new drugs through the early identification of relevant drug efficacy biomarkers.”
“The partnership allows Sanofi-Aventis access to our expert scientists and latest technologies and is an important addition to our translational proteomics partnerships for drug discovery and development,” she continued.